India's indigenous COVID vax likely to get WHO’s nod this week
In July, Bharat biotech submitted its documents comprising its Phase 3 clinical trials data that demonstrated 77.8 percent efficacy to the subject expert committee of the Central Drugs Standard Control Organisation (CDSCO).
Total Views |
New Delhi, September 14: In a major development, the World Health Organisation (WHO) is likely to give its approval to India's indigenously manufactured COVID19 vaccine, Covaxin, for an emergency use listing (EUL), this week.
Covaxin is manufactured by Hyderabad-based pharmaceutical company Bharat Biotech. It is one of the three vaccines that are being administered in the country.
"Within this week we should be able to get WHO Emergency Use Listing (EUL) for Covaxin...Hopefully, the vaccine should be given international recognition so that people travelling abroad have less difficulty," said Dr. NK Arora, Chairman, COVID working group.
In July, Bharat biotech submitted its documents comprising its Phase 3 clinical trials data that demonstrated 77.8 percent efficacy to the subject expert committee of the Central Drugs Standard Control Organisation (CDSCO).
Earlier, WHO Assistant Director-General for vaccines Mariangela Simao had said that the UN health agency's assessment of the Bharat Biotech vaccine was "quite advanced" and officials hoped for a decision by mid-September.
The WHO nod will allow Bharat Biotech to export its vaccine to more nations and it will also ease international travel for people who have been vaccinated with COVAXIN. So far, six vaccines including, Pfizer-BioNTech, AstraZeneca-SK Bio or Serum Institute of India, Johnson & Johnson, Moderna, and Sinopharm have all received WHO approval for COVID-19 vaccines.
.
.